Compare JetBlue Airways Corporation (JBLU) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Zoetis Inc — how do they compare? JetBlue Airways Corporation trades at $3.86 (market cap $1.48B), while Zoetis Inc trades at $74.33 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 20.4× JetBlue Airways Corporation's market cap, and Zoetis Inc pays a 2.9% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Zoetis Inc for 70 Days on average.
| JBLU | ZTS | |
|---|---|---|
Market Cap | $1.48B | $30.20B |
Volume | 30,275,693 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $6.46 | $147.53 |
52-Week Low | $3.92 | $69.09 |
Typical Hold Time | 44 Days | 70 Days |
Enterprise Value | $8.84B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.86, down 2.77% today, reflecting persistent bearish technical signals and weak earnings. The company reported a net loss of $602 million in 2025, with negative profit margins and declining revenue. Recent news includes route expansion to Colombia but also reduced capacity guidance due to weather and fuel costs. Technical indicators are bearish, with the stock trading near support levels.
The outlook remains challenging with high debt levels and consistent losses. Analyst consensus is mixed but leans hold, with a $5.89 price target suggesting potential upside if operational improvements materialize. Key risks include elevated fuel prices, competitive pressure, and macroeconomic sensitivity. Investment appeal is limited to speculative recovery bets amid ongoing fundamental headwinds.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
